华大基因股东拟询价转让4%公司股份；贝达药业拟港股上市丨医药早参

Group 1 - Baiyang Pharmaceutical plans to strategically invest in Jikun Pharmaceutical by acquiring a 24% stake, securing rights to the innovative drug for pulmonary fibrosis, JK1033, and gaining priority purchase rights for all global compound rights of Jikun Pharmaceutical's products [1] - Qianjin Pharmaceutical received approval from the China Securities Regulatory Commission to issue shares and purchase stakes in Hunan Qianjin Xiangjiang Pharmaceutical (28.92%) and Hunan Qianjin Xieli (68%), enhancing its collaboration in the western medicine sector and supporting its "one main, two auxiliary" strategy [2] - BGI Genomics' major shareholder, Shenzhen BGI Genomics Technology Co., plans to transfer 4% of its shares (16.73 million shares) through a pricing inquiry to meet funding needs for cutting-edge technology incubation in cell and spatiotemporal genomics [3] Group 2 - Suoyuan Biotech's key ENLIGHTEN trial results were published in the prestigious journal JAMA Psychiatry, showing significant efficacy of DB104 (Liafensine) in treatment-resistant depression patients with the ANK3 biomarker, marking a breakthrough in precision medicine for mental health [4] - Betta Pharmaceuticals intends to list on the Hong Kong Stock Exchange, reporting a revenue of 1.731 billion yuan in the first half of 2025, a 15.37% increase, but a net profit decline of 37.53% to 140 million yuan, indicating challenges despite growth in revenue [5]